RxDoctor Payments Data

Janish Kothari, MD

Cardiovascular Disease · Brooklyn, NYNPI 1689105033

Payments from drug & device makers

$6,456in general payments, 2019–2025

Across 104 payments — averaging $62.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Abbott$1K
  • Medtronic$588
  • Merck$441
  • Novo Nordisk$396
  • Heartflow, Inc.$368
  • plus $2K from 16 others

What the payments were for

  • Travel & lodging$1,93130%
  • Food & beverage$4,51670%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,456 in reported general payments places this provider in the 70th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$92,567
Medicare patients
1,002
Services billed
2,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan34$23,863
OzempicSemaglutide15$13,888
EliquisApixaban25$13,651
JardianceEmpagliflozin21$12,178
Atorvastatin Calcium86$636
Rosuvastatin Calcium36$493
Nifedipine ErNifedipine38$445
Metoprolol Succinate47$409
Ezetimibe37$364
Valsartan16$351
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide16$336
Amlodipine Besylate41$259
Losartan Potassium52$249
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide33$209
Spironolactone38$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$22$23,86334 claims
Novo NordiskOzempic$396$13,88815 claims
Boehringer IngelheimJardiance$226$12,17821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →